. Author manuscript; available in PMC: 2018 Apr 20.

Published in final edited form as: Ann Intern Med. 2016 Aug 23;165(9):609–616. doi: 10.7326/M16-0271

Table 2.

Baseline Characteristics of Enrolled Patients, by Site

Characteristic	Rhode Island (n = 24)	New York (n = 22)	P Value
Mean age (SD), y	51 (15)	52 (16)	0.86
Female, n (%)	21 (77)	19 (79)	0.85
Mean body mass index (SD), kg/m²	29 (7)	26 (9)	0.24
Median Charlson Comorbidity Index score (range)	0 (0–4)	1 (0–3)	0.22
Mean duration of CDI since initial diagnosis (SD) [range], mo	6 (2) [3–11]	16 (14) [3–48]	0.006
Mean CDI recurrences (SD) [range], n	4 (1) [2–6]	5 (2) [3–10]	<0.001
Mean duration of oral vancomycin therapy (SD) [range], wk^*	15 (7) [7–28]	37 (45) [3–148]	0.22
Prior probiotic treatment, n (%)	20 (83)	13 (59)	0.068
Prior Lactobacillus GG use, n (%)	7 (29)	1 (5)	0.028
Prior Saccharomyces boulardii use, n (%)	15 (63)	9 (41)	0.143
Prior rifaximin use, n (%)	1 (4)	3 (14)	0.26
Prior fidaxomicin use, n (%)	4 (17)	10 (45)	0.034
Proton-pump inhibitor use, n (%)	0 (0)	4 (18)	0.029

CDI = Clostridium difficile infection.

For all prior CDI treatment courses combined; does not necessarily represent continuous use.